BACKGROUND
Patients with relapsed/refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. Herein, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase 3 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Ch...
L. Xie, W. Yao, Y. Hua et al.· Annals of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.